MedTrace Logo

A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression

NCT05932407 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 147777

Last updated 2025-03-03

Study results available
· View outcomes & findings →

Summary

This study is a retrospective database study in Japan to evaluate the relative risk of serious intracranial hemorrhage requiring hospitalization between Vortioxetine tablet treatment and selective serotonin reuptake inhibitor (SSRI) treatment for patients with depression. This survey will conduct in use of medical database called JMDC claims database.

Conditions

Interventions

DRUG

Vortioxetine Tablet

Vortioxetine Tablet

DRUG

SSRI

SSRI: Selective Serotonin Reuptake Inhibitor

Sponsors & Collaborators

Principal Investigators

  • Takeda Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2024-09-09
Completion
2024-09-09

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05932407 on ClinicalTrials.gov